Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IOVA Iovance Biotherapeutics, Inc.

盘后交易 10-20 16:35:32 EDT

14.86

+0.65

+4.57%

盘后14.86

+0.00+0.02%

16:35 EDT

最高14.96	最低13.83	成交量971.12万
今开14.18	昨收14.21	日振幅7.92%
总市值67.31亿	流通市值58.55亿	总股本4.53亿
成交额1.42亿	换手率2.46%	流通股本3.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IOVA","market":"US","secType":"STK","nameCN":"Iovance Biotherapeutics, Inc.","latestPrice":14.86,"timestamp":1792526400000,"preClose":14.21,"halted":0,"volume":9711153,"hourTrading":{"tag":"盘后","latestPrice":14.8631,"preClose":14.86,"latestTime":"16:35 EDT","volume":51451,"amount":764577.140947,"timestamp":1792528517160,"change":0.0031,"changeRate":0.000209,"amplitude":0.005168},"delay":0,"changeRate":0.04574243490499638,"floatShares":394000000,"shares":452971432,"eps":-0.705789,"marketStatus":"盘后交易","change":0.65,"latestTime":"10-20 16:35:32 EDT","open":14.18,"high":14.955,"low":13.83,"amount":142019669.399364,"amplitude":0.07917,"askPrice":14.9,"askSize":4616,"bidPrice":14.8,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.705789,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792540800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":14.21,"preHourTrading":{"tag":"盘前","latestPrice":14.1,"preClose":14.21,"latestTime":"09:28 EDT","volume":16407,"amount":231485.739534,"timestamp":1792502924198,"change":-0.11,"changeRate":-0.007741,"amplitude":0.01822},"postHourTrading":{"tag":"盘后","latestPrice":14.8631,"preClose":14.86,"latestTime":"16:35 EDT","volume":51451,"amount":764577.140947,"timestamp":1792528517160,"change":0.0031,"changeRate":0.000209,"amplitude":0.005168},"volumeRatio":0.887724,"impliedVol":1.0383,"impliedVolPercentile":0.5219},"requestUrl":"/m/hq/s/IOVA","defaultTab":"news","newsList":[{"id":"1124804736","title":"异动解读｜Iovance Biotherapeutics盘中上涨5.36%，ESMO大会展示TIL疗法进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1124804736","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124804736?lang=zh_cn&edition=full","pubTime":"2026-10-19 21:40","pubTimestamp":1792417230,"startTime":"0","endTime":"0","summary":"10月19日，Iovance Biotherapeutics盘中上涨5.36%，报14.535美元/股，成交额1608.62万美元。消息面上，公司宣布将在欧洲肿瘤医学学会大会重点展示跨实体瘤TIL细胞治疗平台，并将以两场口头报告公布一线黑色素瘤及经治非小细胞肺癌中的深度、持久缓解数据，强化市场对其实体瘤细胞疗法商业化与适应症拓展前景的关注。公司此前还将全年营收指引上调至4.10亿至4.20亿美元，高于原先的3.50亿至3.70亿美元，显示Amtagvi与Proleukin需求改善，为此次股价异动提供基本面支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance股价上涨，TIL疗法进展引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149716631","title":"异动解读｜Iovance Biotherapeutics盘中下跌5.54%，报13.9美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149716631","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149716631?lang=zh_cn&edition=full","pubTime":"2026-10-16 21:52","pubTimestamp":1792158722,"startTime":"0","endTime":"0","summary":"10月16日，Iovance Biotherapeutics盘中下跌5.54%，报13.9美元/股，成交额1651.33万美元。Iovance Biotherapeutics所在的生物科技行业中，Moderna, Inc.跌6.49%，艾伯维公司涨0.14%，安进涨0.43%，吉利德科学跌0.62%，福泰制药跌0.12%。公司专注于自体肿瘤浸润淋巴细胞（TIL）疗法的开发与商业化，核心方向包括转移性黑色素瘤等实体瘤治疗。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142850106","title":"异动解读｜Iovance Biotherapeutics盘中上涨5.62%，新任首席医疗官任命落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1142850106","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142850106?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:01","pubTimestamp":1791554476,"startTime":"0","endTime":"0","summary":"10月9日，Iovance Biotherapeutics盘中上涨5.62%，报14.058美元/股，成交额3239.29万美元。消息面上，公司在10月1日宣布任命Noah Berkowitz博士为首席医疗官，该人事变动发生在大幅上调2026年营收指引、股价短期急涨之后，市场在经历回调后重新获得买盘支撑。Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance任命新首席医疗官，股价盘中走高","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152230183","title":"异动解读｜Iovance Biotherapeutics盘中下跌5.27%，任命新任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=1152230183","media":"行情直击","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152230183?lang=zh_cn&edition=full","pubTime":"2026-10-06 22:07","pubTimestamp":1791295628,"startTime":"0","endTime":"0","summary":"10月6日，Iovance Biotherapeutics盘中下跌5.27%，报13.405美元/股，成交额4195.87万美元。消息面上，公司于10月1日宣布任命Noah Berkowitz医学博士为首席医疗官，该人事变动发生在公司大幅上调2026年营收指引、股价短期经历35%以上急涨之后，市场在连续上涨后出现回调。Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Iovance盘中回调，新首席医疗官上任","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121733946","title":"异动解读｜Iovance Biotherapeutics盘中上涨18.29%，上调全年营收指引超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1121733946","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121733946?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:31","pubTimestamp":1790688687,"startTime":"0","endTime":"0","summary":"9月29日，Iovance Biotherapeutics盘中上涨18.29%，报12.96美元/股，成交额5088.31万美元。消息面上，公司最新上调全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，较此前3.5亿至3.7亿美元的指引大幅提升，同时高于FactSet市场一致预期的4.028亿美元。Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance上调全年营收指引，股价强势上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153460492","title":"异动解读｜Iovance Biotherapeutics盘前上涨8.46%，上调全年营收指引超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1153460492","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153460492?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:58","pubTimestamp":1790683127,"startTime":"0","endTime":"0","summary":"9月29日，Iovance Biotherapeutics盘前上涨8.46%，报11.94美元/股，成交额275.78万美元。消息面上，公司最新发布全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，高于FactSet市场一致预期的4.028亿美元。此前公司二季度业绩已大幅超预期，营收约9930万美元创历史新高，每股亏损0.11美元优于市场预期的亏损0.13至0.14美元。Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上调全年营收指引，Iovance盘前上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130392840","title":"异动解读｜Iovance Biotherapeutics盘中上涨8.05%，Q2业绩超预期及投行上调目标价持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1130392840","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130392840?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:31","pubTimestamp":1789655479,"startTime":"0","endTime":"0","summary":"9月17日，Iovance Biotherapeutics盘中上涨8.05%，报10.665美元/股，成交额5973.48万美元，延续近期强势表现。消息面上，公司此前公布的第二季度财报大幅超预期，营收约9931万美元，远超市场预估的8783万美元，每股亏损0.11美元亦优于预期的0.14美元，创下历史最高季度营收纪录。核心产品Amtagvi单季收入约9100万美元，超过UBS预估的8000万美元。UBS随后将公司目标价由4美元上调至7美元，并预计管理层将在三季度业绩发布前上调全年收入指引至3.5亿至3.7亿美元以上。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance业绩超预期，股价大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106126664","title":"异动解读｜Iovance Biotherapeutics盘中上涨8.02%，Q2业绩超预期叠加投行上调目标价提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1106126664","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106126664?lang=zh_cn&edition=full","pubTime":"2026-09-15 00:55","pubTimestamp":1789404920,"startTime":"0","endTime":"0","summary":"9月15日，Iovance Biotherapeutics盘中上涨8.02%，报9.2899美元/股，成交额5794.68万美元。消息面上，公司此前公布的第二季度财报大幅超预期，营收约9931万美元，远超市场预估的8783万美元，每股亏损0.11美元亦优于预期的0.14美元，创下历史最高季度营收纪录。其核心产品Amtagvi单季收入约9100万美元，超过UBS预估的8000万美元。此后UBS将公司目标价由4美元上调至7美元，并预计管理层将在三季度业绩发布前上调全年收入指引至3.5亿至3.7亿美元以上。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance业绩超预期，股价盘中大涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164706243","title":"异动解读｜Iovance Biotherapeutics盘中下跌8.06%，瑞银报告指Amtagvi面临竞争阻力引发回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1164706243","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164706243?lang=zh_cn&edition=full","pubTime":"2026-08-22 02:05","pubTimestamp":1787335528,"startTime":"0","endTime":"0","summary":"8月22日，Iovance Biotherapeutics盘中下跌8.06%，报8.2699美元/股，成交额1.75亿美元。消息面上，瑞银最新发布研究报告指出，公司核心产品Amtagvi面临新兴黑色素瘤疗法的竞争压力，且授权治疗中心的入驻周期仍长达六个月以上，增长前景蒙上阴影。尽管Q2 Amtagvi收入9100万美元超瑞银预估的8000万美元，瑞银仍维持中性评级，目标价由4美元上调至7美元，低于当前市场均值9.33美元。瑞银预计Q3 Amtagvi收入约9600万美元，全年总收入4.05亿美元，但强调市场竞争格局演变或持续施压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance盘中下跌，瑞银警示竞争压力","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117491308","title":"异动解读｜Iovance Biotherapeutics盘中上涨9.07%，Q2业绩大超预期延续上行动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1117491308","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117491308?lang=zh_cn&edition=full","pubTime":"2026-08-20 23:02","pubTimestamp":1787238172,"startTime":"0","endTime":"0","summary":"8月20日，Iovance Biotherapeutics盘中上涨9.07%，报8.715美元/股，成交额1.03亿美元。强劲的Q2财报表现持续驱动股价走强。消息面上，公司于8月6日发布第二季度财报，营收约9930万美元，大幅超出市场预期的8783万美元，创下历史新高；每股亏损0.11美元，优于分析师预期的亏损0.14美元。当前股价仍处于财报发布后的上行通道中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance业绩大超预期，股价强势上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107208733","title":"异动解读｜Iovance Biotherapeutics盘中上涨10.03%，Q2业绩大超预期延续上行动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1107208733","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107208733?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:13","pubTimestamp":1787159599,"startTime":"0","endTime":"0","summary":"8月20日，Iovance Biotherapeutics盘中上涨10.03%，报7.735美元/股，成交额1.04亿美元。强劲的商业化表现推动股价在财报发布后持续走强，当前仍处于业绩驱动的上行通道中。Iovance Biotherapeutics是一家专注于自体肿瘤浸润淋巴细胞疗法开发与商业化的生物技术公司，主要用于治疗转移性黑色素瘤等实体瘤。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145971348","title":"Iovance Biotherapeutics 公布2026年第二季度创纪录营收约9900万美元，并披露业务进展及公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1145971348","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145971348?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:02","pubTimestamp":1786014141,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics（IOVA）近日发布了2026年第二季度的财务报告与业务更新。数据显示，该公司该季度营收飙升至约9900万美元，创下历史新高。与此同时，公司还披露了多项关键业务成就与战略调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105191515","title":"Iovance Biotherapeutics 提交补充招股书，拟增发普通股筹资上限约8970万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105191515","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105191515?lang=zh_cn&edition=full","pubTime":"2026-06-19 04:35","pubTimestamp":1781814938,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司已提交了一份销售协议补充招股说明书，计划增发普通股，最高筹资额约为8970万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126068070","title":"Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1126068070","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126068070?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:05","pubTimestamp":1780517115,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195027615","title":"Iovance Biotherapeutics 公布2026年第一季度积极业绩、业务成就及公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1195027615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195027615?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:07","pubTimestamp":1778152054,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics 重点展示了其2026年第一季度的积极财务业绩、取得的重大业务成就以及重要的公司进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113419522","title":"财报前瞻｜Iovance Biotherapeutics, Inc.本季度营收预计小幅下滑，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1113419522","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113419522?lang=zh_cn&edition=full","pubTime":"2026-04-30 14:38","pubTimestamp":1777531119,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics, Inc.将于2026年05月07日发布财报。市场一致预期本季度Iovance Biotherapeutics, Inc.营收为7,839.63万美元，同比下降4.05%；调整后每股收益为-0.15美元，同比改善37.43%；息税前利润为-6,667.17万美元，同比改善16.71%。公司上季度财报未给出对本季度的明确收入预测指引。公司当前主营业务亮点集中在“产品”业务，上季度收入为2.64亿美元。从近半年公开资料梳理的机构表述看，看多观点占优。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Iovance Biotherapeutics, Inc.本季度营收预计小幅下滑，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517189430","title":"Iovance Biotherapeutics, Inc.2024财年实现净利润-3.72亿美元，同比增加16.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517189430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517189430?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363251,"startTime":"0","endTime":"0","summary":"3月8日，Iovance Biotherapeutics, Inc.公布财报，公告显示公司2024财年净利润为-3.72亿美元，同比增加16.22%；其中营业收入为1.64亿美元，同比增加13681.51%，每股基本收益为-1.28美元。从资产负债表来看，Iovance Biotherapeutics, Inc.总负债2.00亿美元，其中短期债务12.90百万美元，资产负债比为4.55，流动比率为3.75。机构评级：截至2025年3月8日，当前有13家机构对Iovance Biotherapeutics, Inc.目标价做出预测，其中目标均价为20.54美元，其中最低目标价为6.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000219a2647f65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000219a2647f65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517237539","title":"Iovance Biotherapeutics, Inc.盘中异动 下午盘股价大涨5.03%报4.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517237539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517237539?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:22","pubTimestamp":1741202536,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时22分，Iovance Biotherapeutics, Inc.股票出现波动，股价快速上涨5.03%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.06%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306032216963b1b32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306032216963b1b32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677687","title":"Iovance Biotherapeutics, Inc.盘中异动 股价大跌5.07%报3.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677687?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:39","pubTimestamp":1741099151,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时39分，Iovance Biotherapeutics, Inc.股票出现波动，股价急速跳水5.07%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223912989bae64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223912989bae64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152554288","title":"异动解读 | Iovance Biotherapeutics股价盘中暴跌27.66%,分析师下调目标价引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1152554288","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152554288?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:43","pubTimestamp":1740753780,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics(IOVA.US)周五股价盘中大跌27.66%,引发广泛关注。\n\n导致股价暴跌的主要原因是,Baird分析师下调了IOVA的目标股价。Baird维持IOVA的优于大市评级不变,但将其目标价从24美元下调至20美元。\n\n分析师下调目标价反映出外界对该公司前景的担忧。作为一家细胞疗法生物科技公司,Iovance Biotherapeutics致力于开发创新的癌症免疫疗法产品。分析师对公司后续药品管线以及销售增长潜力的预期可能较暗淡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.iovance.com","stockEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":0.3863},{"period":"3month","weight":1.5931},{"period":"6month","weight":3.0255},{"period":"1year","weight":5.5183},{"period":"ytd","weight":4.2051}],"compareEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0243},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.1537},{"period":"ytd","weight":0.124}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞（TIL）治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。该公司于2007年9月17日在内华达州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.029113},{"month":2,"riseRate":0.545455,"avgChangeRate":0.158395},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.048412},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.016024},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.065253},{"month":6,"riseRate":0.5,"avgChangeRate":0.132853},{"month":7,"riseRate":0.666667,"avgChangeRate":0.041289},{"month":8,"riseRate":0.416667,"avgChangeRate":0.083754},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.004561},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.023612},{"month":11,"riseRate":0.727273,"avgChangeRate":0.07065},{"month":12,"riseRate":0.636364,"avgChangeRate":0.051779}],"exchange":"NASDAQ","name":"Iovance Biotherapeutics, Inc.","nameEN":"Iovance Biotherapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Iovance Biotherapeutics, Inc.,IOVA,Iovance Biotherapeutics, Inc.股票,Iovance Biotherapeutics, Inc.股票老虎,Iovance Biotherapeutics, Inc.股票老虎国际,Iovance Biotherapeutics, Inc.行情,Iovance Biotherapeutics, Inc.股票行情,Iovance Biotherapeutics, Inc.股价,Iovance Biotherapeutics, Inc.股市,Iovance Biotherapeutics, Inc.股票价格,Iovance Biotherapeutics, Inc.股票交易,Iovance Biotherapeutics, Inc.股票购买,Iovance Biotherapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}